WuXi Biologics stock forecast
The weighted scenario is HK$78.47 in October 2029, with 55% probability for the base case. It hinges on project cohorts reaching commercial manufacturing and new capacity earning adequate returns.
Where could WuXi Biologics shares be in each forecast year?
The forecast puts WuXi Biologics at HK$56.71 in October 2027, HK$65.61 in October 2028 and HK$78.47 in October 2029, including dividends. That represents returns of 18%, 36% and 63% from HK$48.20 today.
The October 2029 range is much wider: HK$30.65 in the bear case and HK$126.31 in the bull case. The probabilities are 25%, 55% and 20%, so the base case carries the greatest weight.
| Case | Probability | October 2027 | October 2028 | October 2029 |
|---|---|---|---|---|
| Bear | 25 % | 38.97 (-19 %) | 30.71 (-36 %) | 30.65 (-36 %) |
| Base | 55 % | 58.52 (+21 %) | 69.80 (+45 %) | 82.82 (+72 %) |
| Bull | 20 % | 73.90 (+53 %) | 97.71 (+103 %) | 126.31 (+162 %) |
| Weighted | 100 % | 56.71 (+18 %) | 65.61 (+36 %) | 78.47 (+63 %) |
What has to go right for WuXi Biologics, and what could go wrong?
The bear path falls to RMB10,920 million, RMB9,800 million and RMB10,865 million as conversion slows and ramp costs compress margins. The bull path reaches RMB13,536 million, RMB16,080 million and RMB18,810 million as late-stage projects, PPQs and manufacturing improve utilization. WuXi had 78 Phase III and 28 commercial manufacturing projects, with 34 PPQs scheduled for 2026.
| October 2027 | October 2028 | October 2029 | |
|---|---|---|---|
| EBITDA | 12,788 (10,920 / 13,536) | 14,322 (9,800 / 16,080) | 15,980 (10,865 / 18,810) |
| Shares (millions) | 4,105 (4,140 / 4,090) | 4,090 (4,160 / 4,060) | 4,075 (4,180 / 4,030) |
| Enterprise value to ebitda | 15.00 (11.50 / 18.00) | 16.00 (10.00 / 20.00) | 17.00 (9.00 / 22.00) |
| Net debt | -12,853 (-11,853 / -13,853) | -14,053 (-10,853 / -16,353) | -15,853 (-11,353 / -19,853) |
What this means. The negative net debt means the company has more cash than borrowed money, so it has net cash rather than debt.
How much cash does WuXi Biologics really make?
In 2025, operating cash was absorbed by working capital and then reduced by capital projects, leases and interest. The supplied calculation therefore produces a lower free-cash-flow figure than WuXi’s own headline measure. Deducting recurring stock pay produces a stricter view because equity awards still have an economic cost.
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | 6,340.922 | 5,217.257 | 4,667.712 | 5,541.673 | 3,431.258 |
| − Capital spending | 3,685.115 | 3,929.621 | 4,045.574 | 5,868.39 | 6,507.803 |
| = Free cash flow | 2,346.402 | 906.888 | 291.153 | -556.041 | -3,253.588 |
| − Stock pay | 955.055 | 1,215.587 | 1,274.051 | 1,234.383 | 531.923 |
| = Real free cash flow | 1,391.347 | -308.699 | -982.898 | -1,790.424 | -3,785.511 |
What this means. The company's own free cash flow differs from ours because it uses different rules for which cash payments to include, so its number is not directly comparable with ours.
What does an investor pay for WuXi Biologics today?
The valuation therefore contains two ideas. Market capitalization is the value of all shares, while enterprise value adds debt and subtracts cash to approximate the operating business. The trailing P/E compares the share price with profit already earned; the forward P/E uses expected future profit. That gap matters because forecasts must come true. In H1 2026, basic EPS rose 3.4% year on year. Adjusted basic EPS rose 37.3%, helped by the way foreign-exchange and investment items affected reported profit.